Table 2.

Main characteristics of recent phase III randomized clinical trials.

	MINDACT (n = 6693)	TAILORx (n = 9719)	WSG-Plan B (n = 2642)
Study characteristics
Assay	MammaPrint ©	OncotypeDX ©	OncotypeDX ©
Eligible patients	invasive BC, T1-T3, 0–3N+	invasive HR+/HER2− BC, N0, adjuvant CT indication according to NCCN guidelines	invasive HER2− BC, N+ or high risk (≥T2, grade 2–3, age < 35)
Groups and randomization	4 groups according to Clinical risk (Adjuvant! Online) and Genomic risk (MammaPrint ©): ▪C-low/G-low (41%): no CT ▪C-low/G-high (8.8%): randomized (CT vs. not CT) ▪C-high/G-low (23.2%): randomized (CT vs. not CT) ▪C-high/G-high (27%): CT	3 groups according to OncotypeDX ©: ▪RS ≤ 10 (17%): no CT ▪RS 11–25 (69%): randomized (CT vs. no CT) ▪RS ≥ 26 (14%): CT	3 groups according to OncotypeDX ©: ▪RS ≤ 11 (17.8%): randomized (CT vs. no CT) ▪RS 12–25 (61.4%): CT ▪RS ≥ 26 (20.8%): CT
Primary endpoint	5-year DFMS ≥ 92% for C-high/G-low pts who did not receive CT	IDFS non-inferiority of HT alone vs. CT + HT in mid-risk patients	IDFS of low-risk patients treated with HT alone
Population main characteristics
Age	32.2% < 50 years	31.4% < 50 years	median 56 years
Grade 3	28.8%	17.2%	31.2%
HER2+/TNBC	9.5%/9.6%	0%/0%	0%/2.4%
N+	21%	0%	35.2% pN1/6% pN2–3

BC, breast cancer; CT, chemotherapy; DFMS, distant metastasis-free survival; HT, hormone therapy; IDFS, invasive disease-free survival; NCCN, national comprehensive cancer network; TNBC, triple-negative breast cancer.